secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021229
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports Q1 net loss of $6.4M; plans three chronic cough trials in H2 2023
--------------------------------------------------------------------------------

- Net loss of $6.4M in Q1 2023 vs. $7.3M in Q1 2022; cash and equivalents $111.3M.
- Plans to initiate Phase 2b trial for chronic cough in IPF, Phase 1b respiratory physiology trial, and Phase 2a refractory chronic cough trial in H2 2023.
- Received Notice of Allowance for U.S. patent covering oral nalbuphine ER for chronic cough in IPF, expected expiration 2039.
- Completed open-label extension of Phase 2b/3 PRISM trial for prurigo nodularis; will request End of Phase 2 meeting with FDA.
- Completed part 1 of human abuse potential study; selected butorphanol dose for part 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/0000950170-23-021229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/trvi-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer